SIAIP position paper: provocation challenge to antibiotics and non-steroidal anti-inflammatory drugs in children

Caffarelli, Carlo; Franceschini, Fabrizio; Caimmi, Davide; Mori, Francesca; Diaferio, Lucia; Mauro, Dora Di; Mastrorilli, Carla; Arasi, Stefania; Barni, Simona; Bottau, Paolo; Caimmi, Silvia; Cardinale, Fabio; Comberiati, Pasquale; Crisafulli, Giuseppe; Liotti, Lucia; Pelosi, U; Saretta, Francesca; Marseglia, Gian Luigi; Duse, Marzia; Paravati, Francesco

doi:10.1186/s13052-018-0589-3

Cited by 18 publications

(23 citation statements)

References 94 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…An IgE mediated reaction to foods or medications can be considered a potential cause of CU when the reaction develops within one or two hours following allergen exposure and it vanishes in a few hours. Regarding allergic reaction to NSAIDs, they can occur within 24 h. If the interval time between allergen exposure and urticaria occurrence is different, IgE mediated reactions are ruled out and allergy tests (skin prick test [144], serum specific IgE, challenge) to foods [145] and medications [146] should not be performed. Patch tests to foods are not recommended [147].…”

Section: Methodsmentioning

confidence: 99%

Management of chronic urticaria in children: a clinical guideline

et al. 2019

Self Cite

View full text Add to dashboard Cite

The aim of this guidance is to provide recommendations to clinicians and other interested parties on chronic urticaria in children. The Italian Society for Pediatrics (SIP), the Italian Society for Allergy and Immunology (SIAIP), the Italian Society for Pediatric dermatology (SIDerP) convened a multidisciplinary panel that prepared clinical guidelines for diagnosis and management of chronic urticaria in childhood. Key questions on epidemiology, natural history, diagnosis, and management were developed. The literature was systematically searched and evaluated, recommendations were rated and algorithms for diagnosis and treatment were developed. The recommendations focus on identification of diseases and comorbidities, strategies to recognize triggering factors, improvement of treatment by individualized care.

show abstract

Section: Methodsmentioning

confidence: 99%

Management of chronic urticaria in children: a clinical guideline

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…The observation period is at least one hour after administration of the final dose. DPT should be performed by trained personnel to treat severe reactions and by expert allergists [110]. Up to 30% of DPT with BDs may have a negative DPT, therefore a DPT prior to desensitization may decrease the number of patients who need desensitization [106][107][108].…”

Section: Drug Provocation Testmentioning

confidence: 99%

Hypersensitivity Reactions to Monoclonal Antibodies in Children

et al. 2020

Self Cite

View full text Add to dashboard Cite

Biologic drugs are widely used in pediatric medicine. Monoclonal antibodies (mAbs) in particular are a therapeutic option for rheumatic, autoinflammatory and oncologic diseases. Adverse drug reactions and hypersensitivity reactions (HSR) to mAbs may occur in children. Clinical presentation of HSRs to mAbs can be classified according to phenotypes in infusion-related reactions, cytokine release syndrome, both alpha type reactions and type I (IgE/non-IgE), type III, and type IV reactions, all beta-type reactions. The aim of this review is to focus on HSRs associated with the most frequent mAbs in childhood, with particular attention to beta-type reactions. When a reaction to mAbs is suspected a diagnostic work-up including in-vivo and in-vitro testing should be performed. A drug provocation test is recommended only when no alternative drugs are available. In selected patients with immediate IgE-mediated drug allergy a desensitization protocol is indicated. Despite the heavy use of mAbs in childhood, studies evaluating the reliability of diagnostic test are lacking. Although desensitization may be effective in reducing the risk of reactions in children, standardized pediatric protocols are still not available.

show abstract

“…The list of drugs that could be necessary to investigate in children for presumed hypersensitivity includes more common antibiotics and antipyretics, but also chemotherapeutics, perioperative drugs, and biological drugs. Drug provocation tests should always be done by trained personnel and in a setting with facilities to treat adverse reactions [30]. Physicians and nurses should not those involved in the treatment of patients with COVID-19.…”

Section: Drug and Latex Allergymentioning

confidence: 99%

Consensus statement of the Italian society of pediatric allergy and immunology for the pragmatic management of children and adolescents with allergic or immunological diseases during the COVID-19 pandemic

Cardinale

Ciprandi

Barberi³

et al. 2020

Ital J Pediatr

Self Cite

View full text Add to dashboard Cite

The COVID-19 pandemic has surprised the entire population. The world has had to face an unprecedented pandemic. Only, Spanish flu had similar disastrous consequences. As a result, drastic measures (lockdown) have been adopted worldwide. Healthcare service has been overwhelmed by the extraordinary influx of patients, often requiring high intensity of care. Mortality has been associated with severe comorbidities, including chronic diseases. Patients with frailty were, therefore, the victim of the SARS-COV-2 infection. Allergy and asthma are the most prevalent chronic disorders in children and adolescents, so they need careful attention and, if necessary, an adaptation of their regular treatment plans. Fortunately, at present, young people are less suffering from COVID-19, both as incidence and severity. However, any age, including infancy, could be affected by the pandemic. Based on this background, the Italian Society of Pediatric Allergy and Immunology has felt it necessary to provide a Consensus Statement. This expert panel consensus document offers a rationale to help guide decision-making in the management of children and adolescents with allergic or immunologic diseases.

show abstract

SIAIP position paper: provocation challenge to antibiotics and non-steroidal anti-inflammatory drugs in children

Cited by 18 publications

References 94 publications

Management of chronic urticaria in children: a clinical guideline

Management of chronic urticaria in children: a clinical guideline

Hypersensitivity Reactions to Monoclonal Antibodies in Children

Consensus statement of the Italian society of pediatric allergy and immunology for the pragmatic management of children and adolescents with allergic or immunological diseases during the COVID-19 pandemic

Contact Info

Product

Resources

About